

Hallucinogens

Ketamine, LSD, MDMA

Alternative names

- **Ketamine**(K, special K, vitamin K, ket, green, jet, kit-kat, cat valiums, ketalar SV)²
- **LSD** (Acid, cubes, purple haze, raggedy Ann, Sunshine, yellow sunshine, LBJ, peace pill, big D, blotters, domes, hits, tabs, doses, window-pane, microdot, boomers)²
- **MDMA** (Ecstasy, MDMA, "Adam", XTC, E, EVW, love drug, clarity, lover's speed, hugs, beans)²



Characteristics^{2,4}

Ketamine

- NMDA receptor antagonist, prevents glutamate activation, inhibits reuptake of catecholamines (5-HT, NE, DA)
- Used as a club drug at 'raves' and involved in "date rapes"
- Doses of 60-100mg are injected; consciousness is maintained at this dose, but disorientation develops
- Effects start within 60 seconds (IV) and 10-20 min (PO)

LSD

- Most potent hallucinogenic drug
- Psychedelic effects are apparent with a dose of 25-50ug
- Effects begin at 40-60 minutes, peak at 2-4 hours, and gradually return to baseline over 6-8 hours.
- 5-HT₂ receptor agonist
- Used as a club drug at "raves"
- Effects occur in less than 1 hr and last 2-18hrs
- Tolerance develops rapidly; psychological dependence occurs
- Usually combined with cocaine, mescaline, or amphetamine to prolong effects

MDMA

- Causes a calcium-dependent increase in serotonin release into the synaptic cleft and inhibits serotonin reuptake; increases levels of serotonin, norepinephrine, and dopamine
- Typical dose varies from 50-150mg
- Onset of effects is from 30-60minutes, half-life is about 8 hours
- Commonly used at "raves".

Presentation during intoxication²

Common signs and symptoms of intoxication can include²

Ketamine

- | | | |
|---|-------------------------|-------------------------|
| • Nystagmus | • Confusion | • Numbness |
| • Hostility | • Vomiting | • Nausea |
| • Amnesia | • Dream-like state | • Mild delirium |
| • Impaired motor function | • Depersonalization | • Hallucinations |
| • Increased heart rate and blood pressure | • Increased muscle tone | • Stereotypic movements |

Extreme intoxication signs and symptoms may include²:

- | | | |
|-------------------|--------------------------|-------------------------|
| • Severe delirium | • Respiratory depression | • Loss of consciousness |
| • Catatonia | | |

<p>Presentation during intoxication <i>(Continued)</i></p>	<p>LSD:</p> <ul style="list-style-type: none"> • Mydriasis • Muscle tension • Weakness • Agitation • Dysphoria • Nausea • Hyperthermia • Numbness • Visual hallucinations • Panic • Loss of appetite • Hypertension • Tremors • Irrational behaviour • Psychotic reactions <p>MDMA</p> <ul style="list-style-type: none"> • Wakefulness • Depersonalization • Derealization • Headache • Increased endurance and sexual arousal • Hyperthermia • Creates feelings of euphoria and well-being • Increased energy • Salivation • Nausea • Restless legs • Suppressed appetite • Impaired memory and learning • Urinary retention • Heightened tactile sensations • Mydriasis • Trismus • Blurred vision • Thirst • Seizures • Bruxism • Dry mouth
<p>Monitoring and support during intoxication</p>	<p>Ketamine³</p> <ul style="list-style-type: none"> • Presentations are short lived and require symptomatic relief and observation • Low lighting and stimulation should be provided • Levels of patient anxiety should be closely monitored <p>LSD</p> <ul style="list-style-type: none"> • Monitor vital signs⁸ • Monitor mental status • Ensure a low stimuli environment • Provide reassurance as symptoms subside <p>MDMA</p> <ul style="list-style-type: none"> • Monitor vital signs (including temperature)⁸ • Monitor mental status • Monitor for seizures • Monitor for jaundice³ • Ensure a low stimuli environment • Provide reassurance as symptoms subside³ • If hyperthermia occurs, admit to an intensive care unit for intensive support of cardiovascular, respiratory and renal systems³ <p>After effects of MDMA may include;²</p> <ul style="list-style-type: none"> • anorexia • drowsiness • muscle aches • generalized fatigue • irritability • anxiety • depression
<p>Withdrawal presentation</p>	<p>Ketamine (withdrawal symptoms usually last 4-6 days and include)</p> <ul style="list-style-type: none"> • Cravings • Poor appetite • Fatigue • Chills

<p>Withdrawal presentation (Continued)</p>	<ul style="list-style-type: none"> • Restlessness • Anxiety • Tachycardia⁵ <p>LSD</p> <ul style="list-style-type: none"> • Frequent repeated use of psychedelic drugs is unusual, and thus tolerance is not commonly seen. Tolerance may develop to the behavioural effects of LSD after three or four daily doses, but no withdrawal syndrome has been observed ⁴ <p>MDMA</p> <ul style="list-style-type: none"> • Withdrawal is marked by a mood “offset” characterized by depression lasting up to several weeks⁶ • Increased agitation has also been reported during periods of abstinence in chronic MDMA users⁶.
<p>Monitoring and support during withdrawal⁸</p>	<p>Monitor</p> <ul style="list-style-type: none"> • Vital signs • Mental status • Seizure risk • Hydration • Possible serotonin syndrome <p>Interventions</p> <ul style="list-style-type: none"> • Suicide precautions may be necessary • Use calming techniques, reassurance and supportive measures • Benzodiazepines have been used for severe agitation and seizure prevention. • High potency antipsychotics have been used for psychotic symptoms • Antidepressants have been used to treat depression following withdrawal, and to decrease cravings.
<p>Potential Complications</p>	<p>Ketamine</p> <ul style="list-style-type: none"> • Synthetic ketamine has been linked with serious urinary tract infections and bladder-control problems² <p>LSD</p> <ul style="list-style-type: none"> • Psychotic reactions can last several days. Flashbacks may occur without drug being taken² <p>MDMA</p> <ul style="list-style-type: none"> • Severe physical reactions of MDMA include ischemic stroke, fatal brain hemorrhage, and coma. Excessive physical activity may result in disseminated intravascular coagulation, rhabdomyolysis, acute renal and hepatic failure and multiple organ failure. ² • MDMA has also been associated with hyperthermia and hyponatremia (water intoxication). Hyperthermia can become life threatening and is usually accompanied by seizures, disseminated intravascular coagulation, rhabdomyolysis, and renal and liver impairment³ • Hyponatremia is marked by features of confusion, reduced consciousness, and in some cases seizures or convulsions. Symptoms generally resolved as sodium levels are normalized, with full recovery achieved within a few days.³ • Liver damage can occur shortly after ingestion of ecstasy. Most reported cases resolve spontaneously over weeks to months, but a minority progress to full liver failure requiring transplantation ³
<p>Notable Drug interactions</p>	<p>LSD and antidepressants</p> <ul style="list-style-type: none"> • Grand mal seizures have been reported with SSRIs² • Recurrence or worsening of flashbacks have been reported with SSRIs² <p>MDA/MDMA and antidepressants</p> <ul style="list-style-type: none"> • Diminished pharmacological effects of MDMA have been reported ² • Serotonin syndrome and hypertensive crises have been reported in combination with MAOIs²
<p>Psychiatric effects</p>	<ul style="list-style-type: none"> • In the weeks and months after stopping use, a small percentage of people may experience “flashbacks” in which they briefly relive past episodes of drug use. Psychotic symptoms

such as hallucinations, and distortions in the sense of time may persist for extended periods.¹

- Chronic regular use of MDMA may result in mood swings, depression, impulsivity, and lack of self-control, memory loss, and parkinsonism.²
- It is suggested that chronic use of MDMA can produce changes in serotonin function in the CNS and the development of progressive neurodegeneration.²

References

1. Kahan, M. (2014). Physical Effects of Alcohol and Other Drugs. In M.Herie & W. Skinner (Ed.), *Fundamentals of Addiction: A Practical Guide for Counsellors* (4th ed., pp. xiii-xviii). Canada: Centre for Addiction and Mental Health.
2. Bezchlibnyk-Butler, K., Jeffries, J., Procyshyn, R., Virani, A. (2014). *Clinical Handbook of Psychotropic Drugs* (20th ed). Hogrefe Publishing
3. National Centre for Education and Training on Addiction (NCETA) Consortium. (2004), *Alcohol and Other Drugs: A Handbook for Health Professionals*. Australian Government Department of Health and Ageing
4. O'Brien C.P. (2011). Chapter 24. Drug Addiction. In Brunton L.L., Chabner B.A., Knollmann B.C. (Eds), *Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e*. Retrieved April 07, 2015 from <http://accessmedicine.mhmedical.com/content.aspx?bookid=374&Sectionid=41266230>.
- 5 Morgan, C., & Curran, H. (2011) Ketamine use: a review. *Addiction, 107*(1).
- 6 Lüscher C (2012). Chapter 32. Drugs of Abuse. In Katzung B.G., Masters S.B., Trevor A.J. (Eds), *Basic & Clinical Pharmacology, 12e*. Retrieved April 07, 2015 from <http://accessmedicine.mhmedical.com/content.aspx?bookid=388&Sectionid=45764254>
7. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The Pharmacology of Lysergic Acid Diethylamide: A Review. *CNS Neurosci Ther* 14 (2008) 295–314.
8. Townsend, M.C. (2015). *Psychiatric Nursing: Assessment, Care Plans, and Medications*. Oklahoma: F.A. Davis Company.